KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Current Deferred Revenue: 2017-2025

Historic Current Deferred Revenue for Neogenomics (NEO) over the last 8 years, with Sep 2025 value amounting to $2.1 million.

  • Neogenomics' Current Deferred Revenue rose 111.47% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 111.47%. This contributed to the annual value of $745,000 for FY2024, which is 65.02% down from last year.
  • According to the latest figures from Q3 2025, Neogenomics' Current Deferred Revenue is $2.1 million, which was up 36.41% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Neogenomics' Current Deferred Revenue registered a high of $7.6 million during Q4 2022, and its lowest value of $745,000 during Q4 2024.
  • Its 3-year average for Current Deferred Revenue is $2.4 million, with a median of $1.5 million in 2025.
  • As far as peak fluctuations go, Neogenomics' Current Deferred Revenue crashed by 81.14% in 2024, and later surged by 111.47% in 2025.
  • Neogenomics' Current Deferred Revenue (Quarterly) stood at $6.1 million in 2021, then rose by 24.01% to $7.6 million in 2022, then slumped by 71.88% to $2.1 million in 2023, then crashed by 65.02% to $745,000 in 2024, then soared by 111.47% to $2.1 million in 2025.
  • Its Current Deferred Revenue stands at $2.1 million for Q3 2025, versus $1.5 million for Q2 2025 and $1.5 million for Q1 2025.